Compare TLK & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLK | BAX |
|---|---|---|
| Founded | 1884 | 1931 |
| Country | Indonesia | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 13.9B |
| IPO Year | 2002 | 1994 |
| Metric | TLK | BAX |
|---|---|---|
| Price | $12.75 | $24.74 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $27.92 |
| AVG Volume (30 Days) | 815.8K | ★ 6.9M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 7.34% | 0.16% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $11,244,000,000.00 |
| Revenue This Year | $2.36 | $3.33 |
| Revenue Next Year | $2.35 | $2.13 |
| P/E Ratio | ★ $15.71 | $115.64 |
| Revenue Growth | N/A | ★ 5.72 |
| 52 Week Low | $12.38 | $15.73 |
| 52 Week High | $23.52 | $30.00 |
| Indicator | TLK | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 31.86 | 57.61 |
| Support Level | $12.38 | $21.28 |
| Resistance Level | $15.28 | $30.00 |
| Average True Range (ATR) | 0.20 | 0.63 |
| MACD | -0.00 | 0.18 |
| Stochastic Oscillator | 28.35 | 100.00 |
PT Telkom Indonesia (Persero) Tbk is the integrated telecommunications provider in Indonesia. It also provides a wide range of other communication services, including telephone network, interconnection services, multimedia, data and internet communication-related services, satellite transponder leasing, leased line, intelligent network and related services, cable television, and VoIP services. It derives revenue from product lines: Mobile, Consumer, Enterprise, WIB, and Others. The firm has identified five reportable segments, namely B2C, B2B Infra, B2B ICT, International, and Others. The firm generates the majority of its revenue from the B2C segment.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.